Dalane Kitzman to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Dalane Kitzman has written about Diabetes Mellitus, Type 2.
Connection Strength
1.265
-
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):196-209.
Score: 0.122
-
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024 Apr 18; 390(15):1394-1407.
Score: 0.116
-
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023 Aug; 11(8 Pt 1):1000-1010.
Score: 0.109
-
Nassif ME, Windsor SL, Gosch K, Borlaug BA, Husain M, Inzucchi SE, Kitzman DW, McGuire DK, Pitt B, Scirica BM, Shah SJ, Umpierrez G, Austin BA, Lamba S, Khumri T, Sharma K, Kosiborod MN. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. Circ Heart Fail. 2023 Jul; 16(7):e009837.
Score: 0.109
-
Pandey A, Patel KV, Bahnson JL, Gaussoin SA, Martin CK, Balasubramanyam A, Johnson KC, McGuire DK, Bertoni AG, Kitzman D, Berry JD. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial. Circulation. 2020 04 21; 141(16):1295-1306.
Score: 0.087
-
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
Score: 0.082
-
Espeland MA, Dutton GR, Neiberg RH, Carmichael O, Hayden KM, Johnson KC, Jeffery RW, Baker LD, Cook DR, Kitzman DW, Rapp SR. Impact of a Multidomain Intensive Lifestyle Intervention on Complaints About Memory, Problem-Solving, and Decision-Making Abilities: The Action for Health in Diabetes Randomized Controlled Clinical Trial. J Gerontol A Biol Sci Med Sci. 2018 10 08; 73(11):1560-1567.
Score: 0.079
-
Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
Score: 0.077
-
Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
Score: 0.076
-
Unick JL, Gaussoin SA, Hill JO, Jakicic JM, Bond DS, Hellgren M, Johnson KC, Peters AL, Coday M, Kitzman DW, Bossart S, Wing RR. Four-Year Physical Activity Levels among Intervention Participants with Type 2 Diabetes. Med Sci Sports Exerc. 2016 12; 48(12):2437-2445.
Score: 0.069
-
Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. Eur J Prev Cardiol. 2016 May; 23(7):758-68.
Score: 0.063
-
Ribisl PM, Gaussoin SA, Lang W, Bahnson J, Connelly SA, Horton ES, Jakicic JM, Killean T, Kitzman DW, Knowler WC, Stewart KJ. Lifestyle intervention improves heart rate recovery from exercise in adults with type 2 diabetes: results from the Look AHEAD study. J Obes. 2012; 2012:309196.
Score: 0.053
-
Neiberg RH, Wing RR, Bray GA, Reboussin DM, Rickman AD, Johnson KC, Kitabchi AE, Faulconbridge LF, Kitzman DW, Espeland MA. Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study. Obesity (Silver Spring). 2012 Oct; 20(10):2048-56.
Score: 0.050
-
Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012 Jul; 20(7):1511-8.
Score: 0.049
-
Bertoni AG, Kitzman DW. Coronary artery calcium: a clue to the enigma of tight glycemic control and cardiovascular disease? Diabetes. 2009 Nov; 58(11):2448-9.
Score: 0.043
-
Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, Rönnbäck C, Shah SJ, Verma S, Weeke PE, Lincoff AM. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024 Sep 07; 404(10456):949-961.
Score: 0.030
-
Verma S, Butler J, Borlaug BA, Davies M, Kitzman DW, Shah SJ, Petrie MC, Barros E, Rönnbäck C, Vestergaard LS, Schou M, Ezekowitz JA, Sharma K, Patel S, Chinnakondepalli KM, Kosiborod MN. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024 Aug 27; 84(9):773-785.
Score: 0.029
-
Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clin J Am Soc Nephrol. 2015 Sep 04; 10(9):1568-74.
Score: 0.016
-
de Simone G, Kitzman DW, Chinali M, Oberman A, Hopkins PN, Rao DC, Arnett DK, Devereux RB. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J. 2005 May; 26(10):1039-45.
Score: 0.008